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Transforming growth factor b (TGF-b) is a pre-eminent negative
growth factor and/or an apoptotic inducer for epithelial cells (Hata
et al, 1998). Work over the past few years has led to the elucidation
of a TGF-b signal transduction network (Massague, 1998). TGF-b
induces diverse cellular changes through heteromeric complexes
of TGF-b receptor type I (TGF-b RI) and receptor type II (TGF-b
RII), such that the loss of either receptor dramatically alters the
cellular response (Wrana et al, 1994). This network involves the
receptor serine/threonine kinases at the cell surface and their
substrates, Smad proteins (mothers against decapentaplegic),
which move into the nucleus, where they activate target gene tran-
scription in association with DNA-binding partners (Kretzschmar
and Massague 1998).
Mutations in these pathways of TGF-b signalling are the cause
of various forms of human malignancies (Hata et al, 1998).
Among the Smad family members, Smad2 and Smad4 have been
originally isolated as tumour suppressor gene MADR2 and DPC4
respectively (Eppert et al, 1996; Hahn et al, 1996). An additional
role for TGF-b RII as a tumour suppressor gene was demon-
strated by the discovery of inactivating the genome mutations in
the tandem repeat segments, namely microsatellites due to repli-
cation error in colorectal cancers (Markowitz et al, 1995; Wang et
al, 1995). The A10 microsatellite, which is within the coding
region of the extracellular domain of the Type II receptor, is prone
to 1 bp deletions that introduce a stop codon, leading to the
protein truncation, and resistance to TGF-b’s antiproliferative
effect (Grady et al, 1999). Another unstable microsatellite region
has been documented in colon carcinoma: two copies of a dinu-
cleotide repeat (GTGTGT) that, when expanded, lead to an altered
C-terminal amino acid sequence for the receptor (Grady et al,
1999). In this regard, the colorectal microsatellite instability might
play an important role in the pathogenesis. More recently, frequent
mutations of TGF-b RII gene are identified also in colorectal
cancers without microsatellite instability (Grady et al, 1999),
suggesting mutational down-regulation of TGF-b signalling might
be targeted not only by the replication error phenotype.
We have previously reported less frequency of microsatellite
instability in oesophageal carcinomas (Nakashima et al, 1995),
one of the aggressive human cancers (Sugimachi et al, 1994). In
this study, we analysed genetic mutations of TGF-b RII, Smad2,
and Smad4 in these oesophageal samples with microsatellite insta-
bility or stability. Additionally, an effect of our detected mutation
on the TGF-b signalling was analysed in cultured oesophageal
carcinoma cells. This is the first report regarding the relationship
between microsatellite instability and mutational inactivation of
TGF-b in human oesophageal carcinoma.
MATERIALS AND METHODS
We have previously reported detection of microsatellite instability
in six cases of 32 human oesophageal carcinomas obtained from
surgical resection (Nakashima et al, 1995). The genetic mutation
of TGF-b RII, Smad2 and Smad4 was studied in these carcinomas
with or without microsatellite instability and adjacent normal
mucosa. The extracted DNA from tissue samples were used for
further PCR analysis as described previously (Tanaka et al, 1993)
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GAGCAG-3¢, 5¢-GGGACCCCAGGAAGACC-3¢ (exon 1), 
5¢-GGGCTGGTATCAAGTTCATTTG-3¢,5 ¢-GGAGACAGA-
GATACACTGACTGTG-3¢ (exon 2), 5¢-TCCAATGAATCTC-
TTCACTC-3¢, 5¢-CCCACACCCTTAAGAGAAGA-3¢ (exon 3),
5¢-CCAACTCCTTCTCTCCTTGTTTTG-3¢, 5¢-TCCAAGAGG-
CATACTCCTCATAGG-3¢ (exon 4), 5¢-GTCGCTTTGCTGAG-
GTCTATAAGG-3¢,  5¢-CCAGGCTCAAGGTAAAGGGGATCT-
AGCA-3¢ (exon 4), 5¢-GGCGCTGGAATTAAATGATGGGC-3¢,
5¢-GAATAATGCTCGAAGCAACACATG-3¢ (exon 5), 5¢-TTTC-
CTTTGGGCTGCACATG-3¢, 5¢-CCTAAGAGGCAACTTGGTT-
GAATC-3¢ (exon 6), 5¢-CCAACTCATGGTGTCCCTTTG-3¢,
5¢-TCTTTGGACATGCCCAGCCTG-3¢ (exon 7); Smad 2 5¢-
AATCAGCGGGCGGCAGGGT-3¢, 5¢-AGCCCACCTCCGCTT-
CCG-3¢ (exon 1), 5¢-AAGACGGCGGCCGGGAGT-3¢, 5¢-ACG-
CAAACACTTCCCTAGCT-3¢ (exon 1), 5¢-GGTAGTCTCTACA-
TCATCCT-3¢, 5¢-GGCAACTTGAAAGGAACACA-3¢ (exon 2),
5¢-AGTAACCAGCACTACATGCCTGTG-3¢, 5¢-CTTTCAAAA-
TATACCCCCCTCCC-3¢ (exon 3), 5¢-ATCTGCTAGTGCTGC-
TGCA-3¢, 5¢-CCTGGGTCACAAGAGTACT-3¢ (exon 4), 5¢-GTA-
GGTGGACCCTAGCTTT-3¢, 5¢-TTAGGAGATTCAGAAGG-
CAA-3¢ (exon 5), 5¢-GGTAGCTGAGAGAAAAGGTAGTG-3¢,
5¢-TTGGTATGCGTCTCAACTTC-3¢ (exon 6), 5¢-GCCAAAA-
CTGTTGCACCTT-3¢, 5¢-GTGCCAGCAGAAAAGACTT-3¢ (exon
7), 5¢-ACTTCCTGAGCTTTTGCCAGTG-3¢, 5¢-TGCACACAA-
GCTCTTGATGTGG-3¢ (exon 8), 5¢-GCTTCCAAAGTCACA-
CTGA-3¢, 5¢-ATTTGGAGGCCTCCAACTT-3¢ (exons 9–10),
5¢-GCATGTACCTAAACATAGC-3¢, 5¢-CAGAGAAGTGGGA-
ATAACAG-3¢ (exon 11); Smad4 5¢-CGTTAGCTGTTGTTTT-
CACTG-3¢, 5¢-AGAGTATGTGAAGAGATGGAG-3¢ (exon 1),
5¢-TGTATGACATGGCCAAGTTAG-3¢, 5¢-CAATACTCGGTTT-
TAGCAGTC-3¢ (exon 2), 5¢-CTGAATTGAAATGGTTCATGA-
AC-3¢, 5¢-GCCCCTAACCTCAAAATCTAC-3¢ (exon 3),
5¢-TTTTGCTGGTAAAGTAGTATGC-3¢, 5¢-CTATGAAAGATA-
GTACAGTTAC-3¢ (exon 4), 5¢-CATCTTTATAGTTGTGCAT-
TATC-3¢, 5¢-TAATGAAACAAAATCACAGGATG-3¢ (exons
5–6), 5¢-TGAAAGTTTTAGCATTAGACAAC-3¢, 5¢-TGTACT-
CATCTGAGAAGTGAC-3¢ (exon 7), 5¢-TGTTTTGGGTGCAT-
TACATTTC-3¢, 5¢-CAATTTTTTAAAGTAACTATCTGA-3¢ (exon
8), 5¢-TATTAAGCATGCTATACAATCTG-3¢, 5¢-CTTCCACCC-
AGATTTCAATTC-3¢ (exon 9), 5¢-AGGCATTGGTTTTTAATG-
TATG-3¢, 5¢-CTGCTCAAAGAAACTAATCAAC-3¢ (exon 10),
5¢-CCAAAAGTGTGCAGCTTGTTG-3¢, 5¢-CAGTTTCTGTCT-
GCTAGGAG-3¢ (exon) 11). After screening by polymerare chain
reaction-single strand conformation polymorphisms (PCR-SSCP)
method (Tanaka et al, 1993), the PCR products were directly
sequenced by a cycle sequencing procedure (Applied Biochemical
Inc.). Sixteen of cultured cell lines of human oesophageal carci-
noma cells were also analysed (KSE-1, KSE-2, KYSE-30, KYSE-
50, KYSE-110, KYSE-150, KYSE-180, KYSE-200, KYSE-220,
KYSE-410, KYSE-450, TE-1, TE-2, TE-3, TE-4 and TE-5).
The effect of mutant TGF-b RII was assessed by transient
transfection on a human oesophageal carcinoma cell line using
Lipofectamine (Gibco-BRL, Life Technologies, Inc., Gaithersburg,
MD, USA) (Tanaka et al, 1998). The expression plasmids of TGF-
b RII and Smad4 were kindly provided from Dr Michael Reiss
(Yale University) and Dr Joan Massague (Memorial Sloan-
Kettering Cancer Center) respectively. The mutant TGF-b RII
lacking the serine/threonine kinase domain (DKD) was generated
by introduction of a stop codon just before the kinase domain
using the PCR method (Tanaka et al, 1998). Following 10 ng ml–1
of TGF-b1 stimulation, the transfected FLAG-tagged protein was
detected by indirect immunofluorescent technique using anti-
FLAG M2 mouse monoclonal antibody (Eastman Kodak Co.,
Rochester, NY, USA) and anti-immunoglobulin preparation conju-
gated with fluorescence (CAPPEL Research Products, Durham,
NC, USA), as described previously (Tanaka et al, 1998). The
results of cell count were determined by an independent patholo-
gist from three separate experiments.
RESULTS
First, we performed PCR-SSCP and sequencing analysis to detect
genetic mutations of TGF-b RII gene, Smad2 and Smad4 in 32
oesophageal carcinoma tissues, adjacent normal mucosa and 16
carcinoma cell lines (Table 1). Of these 32 carcinomas, microsatel-
lite instability was identified in six cases (Nakashima et al, 1995).
We cannot detect any genetic mutation in Smad2 and Smad4, that
are frequently mutated in colon and pancreas carcinomas respec-
tively (Eppert et al, 1996; Hahn et al, 1996). On the other hand, a
mis-sense mutation of TGF-b RII gene was detected in one tissue
sample of oesophageal carcinoma showing microsatellite stability
(Nakashima et al, 1995). This missense mutation of TGF-b RII
gene (GAC®CAC) caused amino acid substitution from glutamic
acid to glutamine at residue 526 (E526Q). As shown in Figure 1,
the wild-type allele of the gene was also recognized together.
Interestingly, the same mutation has been reported in a TGF-b-
resistant cell line of head and neck carcinoma (Garrigue-Antar et
al, 1995). The amino acid of residue 526 in the TGF-b RII protein,
located within intracellular serine/threonine kinase domain (Figure
2A), was revealed to be essential for the kinase activity (De et al,
1998).
Then, we investigated the effects of the mutant E526Q expres-
sion in the oesophageal carcinoma cells. A human oesophageal
carcinoma cell line KYSE150 was revealed to be sensitive to
TGF-b signals without the mutant components such as RII, Smad2
and Smad4. The mammalian expression vectors of mutant E526Q
were co-transfected together with Smad4 expression vector tagged
with the FLAG-epitope into the KYSE150 oesophageal carcinoma
cell line, followed by analysis of location of the Smad4 protein. As
shown in Figure 2B, nuclear accumulation of Smad4 protein was
recognized in the transfected KYSE150 cells under TGF-b stimu-
lation, indicating intracellular transduction of TGF-b signals. On
the other hand, ectopic expression of the E526Q inhibited the
TGF-b-induced nuclear translocation of Smad4 protein that was
detected in cytoplasm. The similar inhibitory effect was also
observed by transfection of TGF-b RII mutant lacking the kinase
domain (DKD), that is known as the typical dominant negative
mutant (Wrana et al, 1994). Therefore, the mutation of TGF-b RII
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Table 1 Genetic mutation of TGF-b RII, Smad2 and Smad4 in human
oesophageal carcinoma tissues and cell lines
Samples Total TGF-b RII Smad2 Smad4
Carcinoma tissues
Unstable 6 0 0 0
Stable 26 1 (E526Q/wt) 0 0
Normal mucosa tissues 32 0 0 0
Cell lines 16 0 0 0recognized in microsatellite stable oesophageal carcinoma might
make a dominant negative effect on TGF-b signal transduction in
oesophageal carcinoma cells.
DISCUSSION
The microsatellite instability can result from a replication error-
prone phenotype associated with mutations in human DNA
mismatch repair genes homologous to bacterial genes MutS and
MutL, such as hMSH2, hMSH3, hMSH6/GTBP, hMLH1, hPMS1
and hPMS2 (Fishel, 1998). The discovery of a mutation in one of
the principle components of the TGF-b receptor system which is
linked to a DNA repair defect (Markowitz et al, 1995; Wang et al,
1995) represents one possible mechanism of escape from negative
regulatory influences acting upon cells. While microsatellite insta-
bility is identified in almost all malignancies, the frequency is vari-
ously ranged among carcinoma types. Oesophageal carcinoma has
less frequency of instability as shown in our previous reports
(Nakashima et al, 1995). This study demonstrated no genetic
mutation of TGF-b RII gene in the oesophageal carcinomas with
microsatellite instability. It is noteworthy that one mutant TGF-b
RII was found in a sample of microsatellite stable oesophageal
carcinoma. This mis-sense mutation substituted a glutamic acid to
glutamine at residue 526 (E526Q) in the strictly conserved region
of serine/threonine kinase domain (De et al, 1998). The same
mutation has been detected in a neck and head carcinoma cell line,
SqCC/Y1 (Garrigue-Antar et al, 1995). Interestingly, two
microsatellite stable colorectal cancers were recently reported to
have mutant TGF-b RII at residue 522 and residue 528 (Grady et
al, 1999). These mutations are located within kinase subdomain
XI, that is essential for the serine/threonine kinase activity. Thus,
this region XI might be the mutational hot-spots of TGF-b RII
gene independently of microsatellite instability.
TGF-b, one of the potentently negative regulators of epithelial
cells (Hata et al, 1998), induces intracellular signals through
heteromeric receptor complexes of TGF-b RI and TGF-b RII
serine/threonine receptors (Massague, 1998). Receptor activation
occurs upon binding of ligand to TGF-b RII, which then recruits
TGF-b RII mutation in microsatellite stable oesophageal carcinoma 1559
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Figure 1 Sequence analysis of TGF-b RII gene from oesophageal tissue of
normal mucosa (upper), and carcinoma (lower). While nucleotides GAG
encoding glutamic acid (E) at residue 526 was in normal mucosa, the
nucleotides CAG encoding glutamine (Q) were also found with GAG (E) in
oesophageal carcinoma
Figure 2 Effects of the mutant receptor type II on TGF-b signal transduction
for Smad4 protein. (A) Schematic representation demonstrating the structural
and functional domains of wild-type TGF-b RII protein, the missense mutant
E526Q, and the kinase domain-defect mutant DKD. SS, signal sequence;
TM, transmembrane region. (B) Localization of FLAG-tagged Smad4 protein
in co-transfected KYSE150 cells. Nuclear accumulation of Smad4 protein in
40.7 ± 3.5% of mock plasmid cotransfectants after TGF-b stimulation, but
only in 2.1 ± 0.5% of unstimulated mock cotransfectants, as shown in the
panels of mock/Smad4/TGF-b(+) and mock/Smad4/TGF-b(–). Such TGF-b-
induced translocation was abolished in contransfectantion with the missense
mutant TGF-b RII E526Q (3.2 ± 0.9%) or the carboxyl truncated mutant DKD
(3.9 ± 0.8%), as shown in the right two panels. FLAG-tagged Smad4 was
detected by anti-FLAG antibody M2 followed by immunofluorescent
secondary antibody, and the results were determined from three independent
experimentsand phosphorylates TGF-b RI, which propagates the signal to
downstream targets, Smad family proteins. Human Smad family
is composed of at least eight different proteins Smad1–8 that are
classified into three types (Wrana et al, 1994). Upon stimulating
pathway, Class I Smads (Smad1/5/8 and Smad2/3) have been
shown to be directly phosphorylated by TGF-b RI serine/threo-
nine kinase. Class II Smads (Smad4), referred to as ‘co-Smads’,
forms a complex with Class I Smads, which take it into the
nucleus. Formation of this complex is required for optimal
binding and transcriptional activation of target genes in TGF-b
responses. Class III Smads (Smad 6/7) block phosphorylation of
the Class I Smads by binding to the cytoplasmic portion of the
receptors. Expression of the ‘antagonistic Smads’ is induced in
response to the ligands, suggesting that antagonistic Smads
might participate in negative feedback loops to regulate the
intensity and duration of TGF-b responses. Smad2 of Class I and
Smad4 of Class II have been also identified as tumour suppressor
genes mutated in colorectal cancers and pancreatic cancers
respectively. In our present study, any genetic mutation of Smad2
and Smad4 is not observed in either microsatellite unstable 
or stable cancers of oesophagus, suggesting that no Smad 
might function as tumour suppressor genes in oesophageal
carcinogenesis.
There have been several mechanisms reported to acquire resis-
tance to TGF-b in cancer cells. For example, we have previously
identified anti-apoptotic signal transduction against TGF-b,
although intracellular TGF-b signals is clearly recognized in
hepatocellular carcinoma cells (Tanaka and Wands, 1996). By
extension, it seems likely that other antiproliferative or apoptotic
genes could acquire mutations, thereby conferring resistance and
monoclonal expansion. It is also important to consider the possi-
bility that nonmutagenic events could confer resistance to TGF-
b’s antiproliferative effects. Since mutational inactivation of
TGF-b signalling pathways is not frequently occurred under
microsatellite unstable conditions in oesophageal carcinoma,
functional down-regulation or other genetic instability of TGF-b
signalling network should be further investigated (Lengauer et al,
1998).
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